promoted and receive recognition on the basis of productivity, so receiving Bwriting assistance^or being named as an author to a few additional publications was useful for professional advancement. In addition, so long as the academics closely reviewed the article and edited its content to ensure that it reflected their perspectives intellectually, the practice could be rationalized as harmless and justified.
The problem is that authorship in biomedical publications not only provides recognition, but also establishes accountability and responsibility. Key decisions are made during the process of designing and conducting a study and during data analysis and article preparation. Certain issues or findings are prioritized for discussion or given further scrutiny, whereas others are simply not discussed or are even excluded from the publication. Academics who are invited to be guest authors rarely have access to the data for independent analysis, and are only included once the manuscript has first been drafted, after these key decisions regarding presentation of the data have already been made. Ghostwriting goes beyond providing true editorial assistance (i.e., copy-editing), managing references, or table and figure preparation.
Over the past 5 to 10 years, we have finally taken note of these ghosts and unwanted guests. Scandals and litigation have provided heretofore unseen proof of their existence. Litigation related to several pharmaceutical products, including gabapentin (Neurontin), sertraline (Zoloft), conjugated estrogens (Premarin and Prempro), and rofecoxib (Vioxx), [3] [4] [5] provided a unique opportunity whereby court documents could be used to examine the extent of ghostwriting and guest authorship, how these practices were operationalized, and their potential impact on the peer-reviewed biomedical literature. Members of Congress and journalists began their own investigations, leading to front page stories in the New York Times, the Wall Street Journal, and many other newspapers, along with an unprecedented minority staff report from the U.S. Senate Finance Committee led by Senator Charles Grassley.
In response, academic medical centers began establishing formal policies that expressly prohibited ghostwriting and guest authorship, the extent of which is monitored by the American Medical Student Association (AMSA) Scorecard on conflict of interest policies. Similarly, the Pharmaceutical Research and Manufacturers of America (PhRMA), the trade organization representing U.S. pharmaceutical companies, updated its voluntary code of conduct to discourage these practices. In addition, the International Committee of Medical Journal Editors (ICMJE) updated its recommendations to define the role of authors and contributors, establishing clear criteria for evaluating authorship. 6 Moreover, as part of this update, the ICMJE expressly acknowledged that writing assistance can enhance the clinical research dissemination process, and that while medical writers who do not meet the criteria should not be named as authors, they should be acknowledged in the article. 6 Where does that leave us today? In this issue of the Journal of General Internal Medicine, Roper and Korenstein have attempted to answer that question, 7 at least with respect to guest authorship. They identified a sample of randomized trials of drugs and devices that were published in highimpact journals in 2012 and that included details on the role of the trial funder/sponsor, provided an explicit statement of authorship contributions, and were registered on ClinicalTrials.gov, a public registry of clinical trials maintained by the National Library of Medicine. Through an examination of published contributions by first and last authors, they determined that 6 % of trials were guest-authored, a number far below prior estimates of approximately 20 % among articles published in the highest-impact general medical journals. 8, 9 However, among trials for which industry provided funding and played a role in their design, conduct, or analysis, 13 % were determined to have been guestauthored, in contrast to none among trials that either did not receive industry funding, or received industry funding but industry played no collaborative role in the trial design or conduct.
With their use of published authorship contributions, Roper and Korenstein should be applauded for their innovative attempt to better understand a problem that is generally known only through anonymous self-report surveys, investigation and discovery, or litigation documents. However, their study was deliberately conservative, categorizing an article as 'not guest-authored' so long as either the first or last author met authorship criteria. But guest authorship by any author, first, last or otherwise, threatens the integrity of clinical research. Moreover, among trials that either did not receive industry funding or received industry funding but industry played no collaborative role in the trial design or conduct, none were determined to have been guest-authored, raising questions about their methods, given the prevalence of this practice in academic settings. 10 Perhaps authors are applying a lower standard when making statements about authorship contributions, or are falsely inflating their contributions. Furthermore, Roper and Korenstein limited their study to randomized trials published in the highest-impact journals that included statements of funding and authorship contributions and were registered on ClinialTrials.gov. A priori, one would expect that these trials would be among those most likely to be designed and conducted with integrity and to meet ethical standards. Their findings are not generalizable to the many journals that do not provide statements of funding and authorship contributions. Nor are they generalizable to the many observational studies, reviews, meta-analyses, and editorials that populate the pages of the medical literature and are used to inform and influence clinical practice. Finally, it is also important to note that Roper and Korenstein's method could not be used to study ghostwriting, an equally vexing problem for the field.
These limitations suggest that Roper and Korenstein's study should not give a false-sense of 'problem-solved'. Ghosts and unwanted guests continue to haunt the biomedical literature. The steps taken by academic medical centers, PhRMA, the ICMJE and others offer great potential to improve the integrity of clinical research and its dissemination. But more should be done, including clear repercussions for academic authors who continue to utilize ghostwriters and guest author articles, inappropriately taking credit for research in which they did not participate. Biomedical journals might consider retracting these articles, questioning the veracity of their research findings. Clinical research funders, including the National Institutes of Health, might consider permanent or temporary bans on these investigators receiving research support. But at the very least, academic medical centers need to take this information into account when making promotion and leadership decisions. Ghostwriting and guest authorship undermine the integrity of clinical research and should no longer be tolerated.
